PPARG and ovarian cancer: Similarly, growth inhibition via PPARγ activation has been described for liposarcoma [131], gastric cancer [132,133], bladder carcinoma [130,134], renal cell carcinoma [130], neuroblastoma [135,136], glioblastoma [137,138], melanoma [139,140,141,142], NSCLC [143,144], adrenocortical cancer [145,146], hepatocellular carcinoma [147], endometrial carcinoma [148], ovarian cancer [149,150], multiple myeloma [151], B cell lymphoma [152], mesothelioma [153], and esophageal squamous-cell carcinoma [154].